Latest from Sylvester Comprehensive Cancer Center

Jonathan C. Trent, MD, associate director for Clinical Research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses sequencing trabectedin (Yondelis) for patients with soft tissue sarcoma.
Mohammad Jahanzeb, MD, discusses emerging strategies in the adjuvant treatment of patients with HER2-positive breast cancer.
Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process.
Mohammad Jahanzeb, MD, discusses therapeutic agents that may fit into the adjuvant setting treatment paradigm for HER2-positive breast cancer, the increasing importance of genomic testing, and individualized treatments as multiple agents emerge.
Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami's Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.
OncLive  editorial, marketing teams will share news about Sylvester Center.
Mohammad Jahanzeb, MD, discusses impactful studies and other key issues in HER2-positive breast cancer.
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will be one of the sites offering the landmark precision medicine trial, NCI-MATCH – a trial that will open to patient enrollment in July.
Publication Bottom Border
Border Publication